FY2025 EPS Estimates for Zai Lab Lifted by Cantor Fitzgerald

Zai Lab Limited (NASDAQ:ZLAB) – Equities research analysts at Cantor Fitzgerald increased their FY2025 earnings estimates for shares of Zai Lab in a report released on Monday, May 12th. Cantor Fitzgerald analyst L. Watsek now forecasts that the company will post earnings of ($0.82) per share for the year, up from their prior estimate of ($1.46). Cantor Fitzgerald currently has a “Overweight” rating on the stock. The consensus estimate for Zai Lab’s current full-year earnings is ($2.58) per share.

Zai Lab (NASDAQ:ZLAB) last posted its quarterly earnings data on Thursday, May 8th. The company reported ($0.45) EPS for the quarter, topping the consensus estimate of ($0.50) by $0.05. The business had revenue of $106.49 million for the quarter, compared to analyst estimates of $118.40 million. Zai Lab had a negative net margin of 76.14% and a negative return on equity of 36.97%.

A number of other research firms have also weighed in on ZLAB. Scotiabank assumed coverage on Zai Lab in a research report on Friday, March 7th. They set a “sector outperform” rating and a $55.00 price objective for the company. Bank of America reaffirmed a “neutral” rating and issued a $36.10 price target (up previously from $29.00) on shares of Zai Lab in a research report on Monday, March 3rd. Finally, JPMorgan Chase & Co. increased their price objective on shares of Zai Lab from $44.00 to $51.00 and gave the company an “overweight” rating in a research report on Thursday, March 13th.

Zai Lab Stock Performance

ZLAB stock opened at $28.62 on Wednesday. The firm has a 50 day moving average price of $32.62 and a 200-day moving average price of $29.73. Zai Lab has a 52-week low of $16.01 and a 52-week high of $39.77. The firm has a market capitalization of $3.16 billion, a price-to-earnings ratio of -10.33 and a beta of 1.04.

Institutional Investors Weigh In On Zai Lab

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Kingsview Wealth Management LLC raised its stake in Zai Lab by 6.0% during the 1st quarter. Kingsview Wealth Management LLC now owns 9,323 shares of the company’s stock valued at $337,000 after buying an additional 529 shares during the last quarter. GF Fund Management CO. LTD. purchased a new position in shares of Zai Lab in the 4th quarter worth $29,000. Pictet Asset Management Holding SA bought a new stake in shares of Zai Lab in the fourth quarter worth $31,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its position in Zai Lab by 2.1% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 57,114 shares of the company’s stock valued at $1,496,000 after acquiring an additional 1,200 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. increased its position in Zai Lab by 13.4% during the first quarter. China Universal Asset Management Co. Ltd. now owns 12,544 shares of the company’s stock valued at $453,000 after acquiring an additional 1,483 shares during the last quarter. Hedge funds and other institutional investors own 41.65% of the company’s stock.

Insider Activity at Zai Lab

In other Zai Lab news, insider Frazor Titus Edmondson III sold 14,544 shares of the business’s stock in a transaction dated Friday, February 28th. The stock was sold at an average price of $32.98, for a total value of $479,661.12. Following the completion of the transaction, the insider now owns 14,328 shares of the company’s stock, valued at approximately $472,537.44. The trade was a 50.37% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Ying Du sold 50,000 shares of the firm’s stock in a transaction dated Friday, February 28th. The shares were sold at an average price of $34.47, for a total transaction of $1,723,500.00. Following the sale, the chief executive officer now directly owns 494,117 shares in the company, valued at approximately $17,032,212.99. The trade was a 9.19% decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 138,744 shares of company stock valued at $4,685,294. 13.88% of the stock is owned by corporate insiders.

About Zai Lab

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis.